Abstract:Background: Chemotherapy remains a primary treatment method for advanced pancreatic cancer. However, chemotherapy resistance can influence the therapeutic effect of pancreatic cancer. The resistance mechanism of chemotherapeutic agents such as gemcitabine, which is an agent typically used to treat pancreatic cancer, is complicated and can be influenced by genes and the environment. Oridonin is a tetracyclic diterpenoid compound extracted from the traditional Chinese herb Rabdosia labtea. Oridonin may overcome drug resistance in pancreatic cancer, but researching pancreatic cancer drug resistance of chemotherapy by oridonin is not completely understood. Purpose: The present study aimed to assess the impact of oridonin on multidrug resistance proteins, apoptosis-associated proteins and energy metabolism in gemcitabine-resistant PANC-1 (PANC-1/Gem) pancreatic cancer cells. Methods: Gemcitabine resistance in PANC-1/Gem cells was induced using a concentration gradient of gemcitabine. Cell Counting Kit-8 assays were used to detect the impact of gemcitabine and oridonin on the proliferation of PANC-1 and PANC-1/Gem cells. Western blot analysis and immunofluorescence were used to detect the expression of multidrug resistance proteins, apoptosis-associated proteins and low-density lipoprotein receptor protein 1 (LRP1) proteins in PANC-1/Gem cells. The effects of gemcitabine and oridonin on PANC-1/Gem cells apoptosis were detected using flow cytometry. Animal xenograft tumor assays were used to detect the effect of gemcitabine and oridonin on pancreatic cancer in vivo. Furthermore, the ATP Assay kit was used to determine the effects of gemcitabine and oridonin on ATP levels in PANC-1/Gem cells. Immunofluorescence assays were used to detect the effects of gemcitabine and oridonin on the expression of low-density lipoprotein receptor protein 1 (LRP1) in PANC-1/Gem cells. In addition, LRP1 expression was knocked down in PANC-1/Gem cells via lentiviral vector-mediated RNA silencing. Clone formation assays and Western blot analysis were used to detect the effect of LRP1 knockdown on the proliferation of PANC-1/Gem cells. Results: The present results demonstrate that oridonin overcomes PANC-1/Gem cells gemcitabine reistance by regulating GST pi and LRP1/ERK/JNK signaling. Conclusion: In conclusion, the present study indicated that oridonin could overcome gemcitabine resistance in PANC-1/Gem cells by regulating GST pi and LRP1/ ERK/JNK signaling, inducing cell apoptosis. Therefore, oridonin with gemcitabine may be a promising preoperative treatment for patients who suffer from pancreatic cancer.

LY294002 Enhances Inhibitory Effect of Gemcitabine on Proliferation of Human Pancreatic Carcinoma PANC-1 Cells.

Oridonin Overcomes the Gemcitabine Resistant PANC-1/Gem Cells by Regulating GST Pi and LRP/1 ERK/JNK Signalling

Low‑intensity Low‑frequency Ultrasound Enhances the Chemosensitivity of Gemcitabine‑resistant ASPC‑1 Cells Via PI3K/AKT/NF‑κB Pathway‑mediated ABC Transporters.

PI3K Inhibitor LY294002, As Opposed to Wortmannin, Enhances AKT Phosphorylation in Gemcitabine-Resistant Pancreatic Cancer Cells.

Efficacy of Gemcetabine and LY294002 on the Growth of Human Pancreatic Cancer Cell Lines BxPc-3 and MiaPaCa-2

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

Effect of Gemcitabine on Proliferation, Apoptosis and Polo-Like Kinase-1 Expression of Pancreatic Cancer Cell Line AsPC-1

The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells

Β2-Adrenoceptor Blocker Synergizes with Gemcitabine to Inhibit the Proliferation of Pancreatic Cancer Cells Via Apoptosis Induction.

PAK Inhibition by PF-3758309 Enhanced the Sensitivity of Multiple Chemotherapeutic Reagents in Patient-Derived Pancreatic Cancer Cell Lines.

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

Antitumor Effects Of All-Trans Retinoic Acid And Its Synergism With Gemcitabine Are Associated With Downregulation Of P21-Activated Kinases In Pancreatic Cancer

Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer

BMS-754807, a Small-Molecule Inhibitor of Insulin-Like Growth Factor-1 Receptor/insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer.

Inhibition of Sirt1 Combined with Gemcitabine Therapy for Pancreatic Carcinoma

Effects of inhibiting PI3K/AKT/mTOR signaling pathway by LY294002 on gastric cancer MGC-803 cells

Osi-027 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine Both in Vitro and in Vivo

Effect of inhibitory action of LY294002 in the PI3K/AKT signaling pathway on gastric adenocarcinoma SGC-7901 cells

Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.

Synergistic Antitumor Activity of Gemcitabine Combined with Triptolide in Pancreatic Cancer Cells.